Pharma Journalist -

ABM Therapeutics (ABM) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310, a novel small molecule BRAF inhibitor developed…
Read More...

Mind Medicine (MindMed) Inc. announced that it has entered into a license agreement with Catalent, a leader in enabling the development and supply of better treatments for patients…
Read More...

Zuellig Pharma, one of the largest healthcare services groups in Asia, today announced that it has entered into an agreement with global biopharma company, GSK, to help set up its first…
Read More...

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that its partner, Gaelan Medical LLC, a wholly owned subsidiary of the Ghassan Aboud Group (GAG), has received…
Read More...

Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, founded by Longwood Fund, announced the closing of an oversubscribed $31…
Read More...

Allarity Therapeutics, Inc., a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer…
Read More...

Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations,…
Read More...

Pressing issues around care affordability and access threaten US insurance models. We must shift our focus to examining the latest research on the links between out-of-pocket spending…
Read More...

AbbVie and Calibr announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets across AbbVie's core therapeutic growth areas…
Read More...

Gilead Sciences, Inc. announced that the European Commission (EC) approved Trodelvy (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or…
Read More...